Brief: Annexin Reports Promising Topline Results In RVO Phase 2A Study

Annexin Pharmaceuticals AB (publ)

21/08/2024 07:35

Aug 21 (Reuters) - Annexin Pharmaceuticals AB (publ)
 ANNX.ST :
    * ANNEXIN REPORTS PROMISING TOPLINE RESULTS IN RVO PHASE 2A
STUDY
    * INVESTIGATIONAL NEW DRUG CANDIDATE ANXV DEMONSTRATED A
FAVORABLE
SAFETY PROFILE.
    * OUT OF 14 SUBJECTS WHO RECEIVED ANXV AND WERE FOLLOWED FOR
4
MONTHS, 12 IMPROVED OR HAD STABLE DISEASE WITH NO OR A SINGLE
ANTI-VEGF TREATMENT.
    * DATA SUPPORTS FURTHER CLINICAL DEVELOPMENT OF ANXV IN RVO.

Source text for Eikon:  ID:nMFN5kTDdq 
Further company coverage:  ANNX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))